Perspectives from Diabetes Thought Leaders on the Use of GLP-1 Agonists
Leading experts, Anne L. Peters, MD, Ralph A. DeFronzo, MD, Alan J. Garber, MD, PhD, Robert R. Henry, MD, Richard Bergenstal, MD, and others, share their thoughts on GLP-1 therapy....
GLP-1 Notes from the Editor
Welcome to our first edition of our new GLP-1 education series. I am sure that every one of you is familiar with the use of GLP-1 agonists in the treatment of diabetes.
Ever since Bayliss and Starling discovered secretin...
The Incretin Effect
For the complete article, The Incretin Effect, and information on other aspects of GLP-1 treatment, please visit Novo Nordisk's diabetesinamerica at
An African-American Man with Type 2 Diabetes and Obesity
Mr. Slayton is a 64-year-old African-American referred by his primary care physician for evaluation of his type 2 diabetes. His history with type 2 diabetes includes....
Sanofi's Once Daily GLP-1 Lyxumia ® Meets Primary Endpoint in Phase 3 Study
Lyxumia (lixisenatide) when used as an add-on therapy to basal insulin (in association with or without metformin), achieved its primary efficacy endpoint of significantly reducing HbA1c versus placebo for patients with type 2 diabetes...
Can Liraglutide Antibodies Affect Its Efficacy?
Researchers looked at antibody formation when liraglutide (Victoza) is used and whether that has an impact on glycemic efficacy or safety....
Next GLP-1 (Lixisenatide) Achieves Positive Phase III Data in Type 2 Diabetes
Once-Daily Lixisenatide meets primary efficacy endpoint with fewer hypoglycemias than Exenatide twice-daily....
